

Resource Summary Report

Generated by [NIF](#) on Aug 30, 2026

HCT 15

RRID:CVCL_0292

Type: Cell Line

Proper Citation

RRID:CVCL_0292

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0292

Proper Citation: RRID:CVCL_0292

Description: Cell line HCT 15 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Colon adenocarcinoma

Defining Citation: [PMID:427742](#), [PMID:2041050](#), [PMID:7139607](#), [PMID:7247963](#), [PMID:7621404](#), [PMID:7972006](#), [PMID:8197130](#), [PMID:8464898](#), [PMID:9000147](#), [PMID:9000572](#), [PMID:9331090](#), [PMID:9809040](#), [PMID:10700174](#), [PMID:10737795](#), [PMID:11314036](#), [PMID:11414198](#), [PMID:11416159](#), [PMID:11526487](#), [PMID:11668190](#), [PMID:12584437](#), [PMID:15748285](#), [PMID:15900046](#), [PMID:16854228](#), [PMID:17088437](#), [PMID:18167186](#), [PMID:19372543](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20570890](#), [PMID:20606684](#), [PMID:22068913](#), [PMID:22336246](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22628656](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24042735](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:24755471](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25926053](#), [PMID:25944804](#), [PMID:26169745](#), [PMID:26537799](#), [PMID:26589293](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:28179481](#), [PMID:28192450](#), [PMID:28196595](#), [PMID:28683746](#), [PMID:28854368](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31733513](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Population: Caucasian., Part of: RAS genetic alteration cell panel (ATCC TCP-1031)., Part of: PI3K genetic alteration cell panel (ATCC TCP-1028)., Part of: NCI-60 cancer cell line panel., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCT 15

Synonyms: HCT-15, HCT.15, HCT15

Cross References: BTO:BTO_0002201, CLO:CLO_0003666, EFO:EFO_0002188, MCCL:MCC:0000182, CLDB:cl1576, CLDB:cl4985, ABM:T8966, AddexBio:C0009010/381, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CCL-225, BCRC:60539, BioGRID_ORCS_Cell_line:868, BioSample:SAMN01821556, BioSample:SAMN01821630, BioSample:SAMN03471553, BioSample:SAMN10987770, cancerellines:CVCL_0292, CCRID:1101HUM-PUMC000247, CCRID:3101HUMTCHu133, CCRID:4201HUM-CCTCC00250, CCTCC:GDC0250, Cell_Model_Passport:SIDM00789, ChEMBL-Cells:ChEMBL3307945, ChEMBL-Targets:ChEMBL612263, CLS:300229, ColonAtlas:HCT15, Cosmic:711261, Cosmic:873700, Cosmic:875902, Cosmic:887222, Cosmic:897458, Cosmic:905007, Cosmic:905937, Cosmic:913889, Cosmic:934567, Cosmic:947354, Cosmic:995403, Cosmic:1044258, Cosmic:1057756, Cosmic:1066206, Cosmic:1092601, Cosmic:1122324, Cosmic:1132569, Cosmic:1175841, Cosmic:1184092, Cosmic:1187307, Cosmic:1218878, Cosmic:1305354, Cosmic:1310950, Cosmic:1312338, Cosmic:1436020, Cosmic:1466814, Cosmic:1479592, Cosmic:1526922, Cosmic:1609492, Cosmic:1676747, Cosmic:1708403, Cosmic:1995438, Cosmic:1998443, Cosmic:2036655, Cosmic:2156942, Cosmic:2301979, Cosmic:2664053, Cosmic:2727470, Cosmic:2760066, Cosmic:2800585, Cosmic:2811051, Cosmic-CLP:905937, DepMap:ACH-000997, DSMZ:ACC-357, DSMZCellDive:ACC-357, ECACC:91030712, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:905937, GEO:GSM2129, GEO:GSM50189, GEO:GSM50253, GEO:GSM206502, GEO:GSM274763, GEO:GSM274764, GEO:GSM481406, GEO:GSM513816, GEO:GSM514293, GEO:GSM741257, GEO:GSM743444, GEO:GSM750792, GEO:GSM784011, GEO:GSM799332, GEO:GSM799395, GEO:GSM844554, GEO:GSM846356, GEO:GSM887063, GEO:GSM888133, GEO:GSM1153402, GEO:GSM1178151, GEO:GSM1178152, GEO:GSM1178153, GEO:GSM1181251, GEO:GSM1181363, GEO:GSM1346875, GEO:GSM1374519, GEO:GSM1374520, GEO:GSM1374521, GEO:GSM1374522, GEO:GSM1448178, GEO:GSM1669869, GEO:GSM2124665, GEO:GSM2550002, IARC_TP53:21114, ICLC:HTL00001, IGRhCellID:HCT15, KCB:KCB 2011097YJ, KCLB:10225, LiGeA:CCLE_761, LINCS_LDP:LCL-1178, Lonza:492, MetaboLights:MTBLS227, NCI-DTP:HCT-15, PharmacDB:HCT15_518_2019, PRIDE:PXD003539, PRIDE:PXD005235, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_0292, PubChem_Cell_line:CVCL_0292, RCB:RCB1958, SKY/M-FISH/CGH:2786, TKG:TKG 0504, TOKU-E:1423, Wikidata:Q54882006

ID: CVCL_0292

Hierarchy: cvcl_3449

Record Creation Time: 20220427T220321+0000

Record Last Update: 20260829T233638+0000

Ratings and Alerts

No rating or validation information has been found for HCT 15.

Warning: Discontinued: RCB; RCB1958

Population: Caucasian., Part of: RAS genetic alteration cell panel (ATCC TCP-1031)., Part of: PI3K genetic alteration cell panel (ATCC TCP-1028)., Part of: NCI-60 cancer cell line panel., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 950 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Chantzoura E, et al. (2026) The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity. Cancer immunology research, 14(2), 243.

Kamgar M, et al. (2026) Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma. Cancer research, 86(8), 2042.

Yokomura M, et al. (2026) Afatinib exerts an inhibitory effect on T cell-mediated cytotoxicity. Cancer immunology, immunotherapy : CII, 75(1), 33.

Wang B, et al. (2026) MYLK4 promotes colorectal cancer progression by regulating lipid metabolism reprogramming via targeting ferroptosis. Neoplasia (New York, N.Y.), 73, 101270.

Watlington WK, et al. (2026) Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation. Molecular oncology.

Takano K, et al. (2026) DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. Molecular cancer therapeutics, 25(1), 7.

Lentz RW, et al. (2026) Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model. Frontiers in oncology, 16, 1721685.

Zhuang X, et al. (2026) Receptor-ubiquitination-targeting antibody-drug conjugates for enhanced endocytosis and lysosomal delivery. Cell chemical biology, 33(4), 506.

- Baars B, et al. (2026) RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors. *Molecular cancer research : MCR*, 24(1), 60.
- Duan X, et al. (2026) DDR1 Promotes Immune Evasion in Colorectal Cancer by Orchestrating IL33-Mediated M2-like Polarization of Tumor-Associated Macrophages. *Cancer immunology research*, 14(6), 900.
- Yue Z, et al. (2026) Subcellular Redistribution of Endomembrane GPR15 Promotes NAD⁺-Mediated Metabolic Reprogramming and Boosts 5-FU Chemosensitivity in Colorectal Cancer. *Cancer research*, 86(9), 2253.
- Dong Z, et al. (2026) Molecular Mechanism of NSUN6-Mediated Epigenetic Modifications in the Malignant Progression of Colorectal Cancer Cells. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 40(10), e71883.
- Hosogane M, et al. (2026) Variant-specific interaction of kinectin 1 with the multi-tRNA synthetase complex regulates ER sheet organization. *iScience*, 29(1), 114303.
- Ebata Y, et al. (2026) Proteasome inhibitor, ixazomib prevents topoisomerase-I degradation and reverses irinotecan resistance in colorectal cancer. *Molecular oncology*.
- Xiao X, et al. (2026) Single-Mitochondrion ATP Profiling Directs Discovery of Targetable OXPHOS Dependency in Cancers. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(21), e13341.
- Choi PH, et al. (2026) Distinct ERK and PI3K dependencies mediate a heterogeneous response to RAS(ON) inhibition in KRAS-mutant colorectal cancer. *Cell reports*, 45(7), 117559.
- Huang M, et al. (2026) KRT81 promotes metastasis of colorectal cancer by acting as a protein scaffold for ezrin. *Oncogene*, 45(3), 459.
- Zhan W, et al. (2026) Cathepsin-D-mediated MHC class I degradation contributes to immune evasion in colorectal cancer. *Cell reports. Medicine*, 102534.
- Lee CJ, et al. (2026) The dysadherin/carbonic anhydrase 9 axis shapes an acidic tumor microenvironment to promote colorectal cancer progression. *Signal transduction and targeted therapy*, 11(1), 19.
- Bai??o A, et al. (2026) Targeted nanoparticle delivery of irinotecan enhances tumor response to PD-L1 blockade in colorectal cancer. *Journal of controlled release : official journal of the Controlled Release Society*, 391, 114609.